<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Vet Res</journal-id><journal-id journal-id-type="iso-abbrev">BMC Vet. Res</journal-id><journal-title-group><journal-title>BMC Veterinary Research</journal-title></journal-title-group><issn pub-type="epub">1746-6148</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28629456</article-id><article-id pub-id-type="pmc">5477108</article-id><article-id pub-id-type="publisher-id">1108</article-id><article-id pub-id-type="doi">10.1186/s12917-017-1108-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comparison of the effects of 7.2% hypertonic saline and 20% mannitol on whole blood coagulation and platelet function in dogs with suspected intracranial hypertension - a pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yozova</surname><given-names>Ivayla D.</given-names></name><address><email>i.yozova@massey.ac.nz</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Howard</surname><given-names>Judith</given-names></name><address><email>judith.howard@vetsiusse.unibe.ch</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Henke</surname><given-names>Diana</given-names></name><address><email>diana.henke3004@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dirkmann</surname><given-names>Daniel</given-names></name><address><email>Daniel.Dirkmann@uk-essen.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8762-9068</contrib-id><name><surname>Adamik</surname><given-names>Katja N.</given-names></name><address><email>katja.adamik@vetsuisse.unibe.ch</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.148374.d</institution-id><institution>Institute of Veterinary, Animal and Biomedical Sciences, </institution><institution>Massey University, </institution></institution-wrap>Private Bag 11-222, Palmerston North, 4442 New Zealand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution>Clinical Diagnostic Laboratory, Department of Clinical Veterinary Medicine, </institution><institution>Vetsuisse Faculty, University of Bern, </institution></institution-wrap>Laenggassstrasse 124, 3012 Bern, Switzerland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution>Division of Neurological Sciences, </institution><institution>Vetsuisse Faculty, University of Bern, </institution></institution-wrap>Laenggassstrasse 128, 3012 Bern, Switzerland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0262 7331</institution-id><institution-id institution-id-type="GRID">grid.410718.b</institution-id><institution>Clinic for Anesthesiology and Intensive Care, </institution><institution>Essen University Hospital, </institution></institution-wrap>Hufelandstra&#x000df;e 55, 45122 Essen, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution>Division of Small Animal Emergency and Critical Care, Department of Clinical Veterinary Medicine, </institution><institution>Vetsuisse Faculty, University of Bern, </institution></institution-wrap>Laenggassstrasse 128, 3012 Bern, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>13</volume><elocation-id>185</elocation-id><history><date date-type="received"><day>2</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Hyperosmolar therapy with either mannitol or hypertonic saline (HTS) is commonly used in the treatment of intracranial hypertension (ICH). In vitro data indicate that both mannitol and HTS affect coagulation and platelet function in dogs. The aim of this study was to compare the effects of 20% mannitol and 7.2% HTS on whole blood coagulation using rotational thromboelastometry (ROTEM&#x000ae;) and platelet function using a platelet function analyzer (PFA&#x000ae;) in dogs with suspected ICH. Thirty client-owned dogs with suspected ICH needing osmotherapy were randomized to receive either 20% mannitol (5&#x000a0;ml/kg IV over 15&#x000a0;min) or 7.2% HTS (4&#x000a0;ml/kg IV over 5&#x000a0;min). ROTEM&#x000ae; (EXTEM&#x000ae; and FIBTEM&#x000ae; assays) and PFA&#x000ae; analyses (collagen/ADP cartridges) were performed before (T<sub>0</sub>), as well as 5 (T<sub>5</sub>), 60 (T<sub>60</sub>) and 120 (T<sub>120</sub>) minutes after administration of HTS or mannitol. Data at T<sub>5</sub>, T<sub>60</sub> and T<sub>120</sub> were analyzed as a percentage of values at T<sub>0</sub> for comparison between groups, and as absolute values for comparison between time points, respectively.</p></sec><sec><title>Results</title><p>No significant difference was found between the groups for the percentage change of any parameter at any time point except for FIBTEM&#x000ae; clotting time. Within each group, no significant difference was found between time points for any parameter except for FIBTEM&#x000ae; clotting time in the HTS group, and EXTEM&#x000ae; and FIBTEM&#x000ae; maximum clot firmness in the mannitol group. Median ROTEM&#x000ae; values lay within institutional reference intervals in both groups at all time points, whereas median PFA&#x000ae; values were above the reference intervals at T<sub>5</sub> (both groups) and T<sub>60</sub> (HTS group).</p></sec><sec><title>Conclusions</title><p>Using currently recommended doses, mannitol and HTS do not differ in their effects on whole blood coagulation and platelet function in dogs with suspected ICH. Moreover, no relevant impairment of whole blood coagulation was found following treatment with either solution, whereas a short-lived impairment of platelet function was found after both solutions.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Intracranial hypertension</kwd><kwd>Osmotherapy</kwd><kwd>Hypertonic saline</kwd><kwd>Mannitol</kwd><kwd>Hemostasis</kwd><kwd>Thromboelastometry</kwd><kwd>Platelet function</kwd></kwd-group><funding-group><award-group><funding-source><institution>Specialization Commission (SPEZKO) of the Vetsuisse Faculty of Bern, Switzerland</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Osmotherapy is commonly used in the treatment of intracranial hypertension (ICH) due to a variety of causes, including head trauma, intracranial neoplasia, infection or hemorrhage, and status epilepticus [<xref ref-type="bibr" rid="CR1">1</xref>]. The principle goal of osmotherapy is to shift fluid from the intracellular into the extracellular compartment using intravenous hyperosmolar agents, thereby reducing brain edema and improving cerebral perfusion pressure [<xref ref-type="bibr" rid="CR2">2</xref>]. Although 10&#x02013;20% mannitol is considered the gold standard hyperosmolar agent in the treatment of ICH [<xref ref-type="bibr" rid="CR3">3</xref>], mannitol-induced osmotic diuresis may cause hypovolemia and reduction in cerebral perfusion pressure [<xref ref-type="bibr" rid="CR1">1</xref>]. In recent years, 3.0&#x02013;7.5% hypertonic saline (HTS) has gained popularity in the treatment of ICH [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] as it has less pronounced diuretic effects and therefore does not cause hypovolemia [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Indeed, in the face of hypovolemic shock and traumatic brain injury, HTS provides the advantage of volume expansion, restoring adequate cerebral perfusion pressures, and reducing brain edema, which makes it superior to mannitol in trauma patients with shock [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Both mannitol and HTS have been shown to interfere with whole blood coagulation and platelet function [<xref ref-type="bibr" rid="CR9">9</xref>]. This is in part due to dilutional coagulopathy. Furthermore, 7.2% HTS may directly disturb both fibrin formation and platelet function [<xref ref-type="bibr" rid="CR10">10</xref>], and mannitol may interfere with coagulation by reducing clot strength [<xref ref-type="bibr" rid="CR11">11</xref>]. In addition, hyperosmolarity is supposed to lead to impairment of both whole blood coagulation and platelet function [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In consequence, the safety of using these agents in patients with ICH and intracranial hemorrhage remains unclear [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Previous in vitro studies in humans have demonstrated anticoagulant effects of both mannitol and HTS [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], although one clinical study failed to demonstrate any negative effect on hemostasis using either solution in patients undergoing elective intracranial surgery [<xref ref-type="bibr" rid="CR15">15</xref>]. Similarly, in vitro studies in dogs demonstrated that both mannitol and HTS have negative effects on coagulation in a dose-dependent fashion, although in vivo studies in dogs in a clinical setting are lacking [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. As a result, current guidelines for osmotherapy in dogs with ICH are largely extrapolated from experimental data and human literature [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p>The aim of this study was to compare the effects of clinically recommended doses of 20% mannitol and 7.2% HTS on whole blood coagulation using rotational thromboelastometry (ROTEM&#x000ae;) and on platelet function using a platelet function analyzer (PFA&#x000ae;) in dogs with suspected ICH. Based on a previous canine in vitro study, we expected that mannitol would have a greater impact on coagulation than HTS [<xref ref-type="bibr" rid="CR17">17</xref>]. A second aim was to compare plasma osmolarity after either osmotherapeutic solution. Knowledge of the extent to which these solutions may impact global hemostasis may influence clinical decision-making in the selection of solutions for individual dogs.</p></sec><sec id="Sec2"><title>Methods</title><p>The study was designed as a prospective, randomized, non-blinded cohort study using client-owned dogs with suspected ICH. The trial was approved the Animal Experiment Committee of the Swiss Federal Veterinary Office (registration number BE 90/13), and informed owner consent was obtained for all dogs.</p><sec id="Sec3"><title>Animals</title><p>Dogs with suspected ICH requiring osmotherapy were enrolled between March 2013 and March 2016. A tentative diagnosis of ICH was based on history, neurologic examination (performed by a board-certified neurologist) and/or magnetic resonance or computed tomographic imaging studies (evaluated by a board-certified radiologist or neurologist). Criteria to substantiate suspicion of ICH were a forebrain or multifocal localization with severely reduced consciousness and miotic pupils on neurological exam, Cushing triad (irregular respiration, bradycardia, and systolic hypertension), brain herniation or other shifts of brain parenchyma on MRI or CT [<xref ref-type="bibr" rid="CR20">20</xref>], an elevated resistive index [<xref ref-type="bibr" rid="CR21">21</xref>], and deterioration of modified Glasgow coma scale scores [<xref ref-type="bibr" rid="CR22">22</xref>]. The decision to administer osmotherapy was at the clinicians&#x02019; discretion. Exclusion criteria were azotemia (plasma creatinine concentration&#x000a0;&#x0003e;&#x000a0;140&#x000a0;&#x003bc;mol/L), body weight&#x000a0;&#x0003c;&#x000a0;7&#x000a0;kg, age&#x000a0;&#x0003c;&#x000a0;6&#x000a0;months or &#x0003e;12&#x000a0;years, presence of diseases known to affect coagulation (hyperadrenocorticism, protein losing enteropathy or nephropathy, and hepatic insufficiency) and administration of non-steroidal anti-inflammatory drugs, osmotherapeutics (mannitol, HTS), artificial colloids, or blood products within two weeks prior to study enrollment. In addition, dogs were excluded if their initial hematocrit was below 0.25&#x000a0;L/L or if platelet counts were below 100&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>/L, as this may influence results PFA assays [<xref ref-type="bibr" rid="CR23">23</xref>]. Clinical data collected included patient characteristics (breed, age, gender, and body weight), the underlying disease causing ICH, and any additional crystalloid fluid therapy administered within the measurement period.</p></sec><sec id="Sec4"><title>Treatment groups</title><p>Osmotherapeutic solutions used in this study were 20% mannitol (Dr. G. Bichsel AG, Interlaken, Switzerland) (osmolarity, 1100&#x000a0;mOsm/L) and 7.2% HTS (Dr. G. Bichsel AG, Interlaken, Switzerland) (osmolarity, 2464&#x000a0;mOsm/L). Dogs were randomized to receive either solution by selecting a sealed envelope containing a numbered card. Dogs received either 1&#x000a0;g/kg (5&#x000a0;ml/kg) mannitol administered over 15&#x000a0;min or 4&#x000a0;ml/kg HTS administered over 5&#x000a0;min using a syringe pump. Additional crystalloid fluid therapy given during the measurement period was at the clinician&#x02019;s discretion. Animals were excluded if additional osmotherapy was administered during the study measurement period.</p></sec><sec id="Sec5"><title>Measurements</title><p>Whole blood coagulation was analyzed using ROTEM&#x000ae; (ROTEM&#x000ae;, TEM Innovations GmbH, Munich, Germany), according to the manufacturer&#x02019;s instructions using methods previously described for canine samples [<xref ref-type="bibr" rid="CR24">24</xref>]. Two ROTEM&#x000ae; machines were available to enable parallel measurements of T<sub>0</sub> and T<sub>5</sub> samples. Clotting activators used were EXTEM&#x000ae; (re-calcification and tissue factor activation) for assessment of the extrinsic pathway and FIBTEM&#x000ae; (tissue factor activation and platelet inhibition with cytochalasin D) for analysis of the extrinsic pathway and qualitative assessment of fibrinogen status (star-tem&#x000ae;, ex-tem&#x000ae;, and fib-tem&#x000ae; reagents, TEM Innovations GmbH, Munich, Germany). Data collected were clotting time (the time from the start of the measurement until the onset of clotting, CT), clot formation time (the time between the onset of clotting and a clot firmness of 20&#x000a0;mm amplitude, CFT), alpha angle (angle between the baseline and a tangent to the clotting curve through the 2&#x000a0;mm CT, &#x003b1;), and amplitude 10 (clot firmness in mm at the amplitude time point of 10&#x000a0;min after CT, A10), and maximum clot firmness (the maximum amplitude of the curve measured in millimeters, MCF). Platelet function was assessed using a PFA-100&#x000ae; analyzer (PFA-100&#x000ae;; Siemens Healthcare Diagnostics AG, Zurich, Switzerland), according to the manufacturer&#x02019;s instructions using methods previously described for canine samples [<xref ref-type="bibr" rid="CR23">23</xref>] and collagen/ADP cartridges (Dade PFA Collagen/ADP Test Cartridge, Siemens Healthcare Diagnostics AG, Zurich, Switzerland). Briefly, the time until occlusion of the aperture by platelet plug formation (closure time, Ct<sub>PFA</sub>) was measured. Institutional reference intervals (RI) for ROTEM&#x000ae; and PFA&#x000ae; used in this study were previously established from jugular blood samples of 37 healthy dogs. Hematocrits and platelet counts were measured using a hematology analyzer (Advia&#x000ae; 120, Siemens Healthcare Diagnostics AG, Zurich, Switzerland) and plasma osmolarity was measured using a freezing-point osmometer (Osmometer Type 1, Loeser Messtechnik, Germany).</p></sec><sec id="Sec6"><title>Blood sampling</title><p>Blood samples were obtained prior to (T<sub>0</sub>), and five (T<sub>5</sub>), 60 (T<sub>60</sub>), and 120&#x000a0;min (T<sub>120</sub>) after the end of osmotherapy administration. At each time point, blood was obtained by careful puncture of the lateral saphenous vein using a 21G butterfly needle connected to a vacutainer system. To minimize contamination of the whole blood samples with tissue factor, the first and third blood samples were collected from the right saphenous vein and the second and fourth from the left saphenous vein. Blood was collected in the following order: one serum vacutainer tube (discard tube), two 3.2% buffered sodium citrate vacutainer tubes (BD Vacutainer 1.8&#x000a0;ml coagulation tube, buffered trisodium citrate 3.2%, BD, Plymouth, United Kingdom) for PFA&#x000ae; and ROTEM&#x000ae; analyses, one heparin tube (Li-Heparin LH/1.3, 1.3&#x000a0;ml tubes, Sarstedt AG, Sevelen, Switzerland) for osmolarity and one K<sub>2</sub>-EDTA tube (K2-EDTA 2&#x000a0;ml tubes, Sarstedt AG, Sevelen, Switzerland) for hematocrit and platelet counts. Blood samples for ROTEM&#x000ae; and PFA&#x000ae; analyses were maintained at room temperature and analyses were started after 30-60&#x000a0;min. Hematocrits, platelet counts and osmolarity were measured within 4&#x000a0;h of sampling. All blood samples were collected and analyzed by the same investigator (IY).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>Descriptive statistics were evaluated and continuous variables were assessed for normality using the D&#x02019;Agostino-Pearson test and by examining normal plots. Differences between groups (mannitol vs HTS) were evaluated using independent samples t-tests and Mann-Whitney tests for normal and non-normal distributed continuous data, respectively, and chi-squared tests were used for categorical data. For comparison between the groups for ROTEM&#x000ae; and PFA&#x000ae; assays, data at T<sub>5</sub>, T<sub>60</sub> and T<sub>120</sub> were evaluated as a percentage of the values measured at T<sub>0</sub> in each dog.</p><p>Repeated measures analyses within each group for osmolarity were performed using a Friedman test and post-hoc pair-wise analysis was applied using Wilcoxon tests with Bonferroni correction. Repeated measures analyses within each group for ROTEM&#x000ae; and PFA&#x000ae; measurements were performed using a Skillings-Mack test, which is a generalization of the Friedman test for incomplete blocks when observations are missing arbitrarily. All data were analyzed using statistical software (MedCalc&#x000ae; version 16.4.3, MedCalc&#x000ae; Software bvba, Ostend, Belgium and Statext version 2.7.17, Statext LLC, Wayne NJ, USA) and significance was set at <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 throughout.</p></sec></sec><sec id="Sec8"><title>Results</title><p>A total of 30 dogs were included in the study (15 dogs in each group). Dogs had a mean age of 6.2&#x000a0;&#x000b1;&#x000a0;3.4&#x000a0;years and a mean body weight of 25.9&#x000a0;&#x000b1;&#x000a0;13.6&#x000a0;kg. There were 13 female dogs (5 sexually intact, 8 spayed) and 17 male dogs (8 sexually intact, 9 castrated). No significant difference was found between groups for age (<italic>P</italic>&#x000a0;=&#x000a0;0.99), body weight (<italic>P</italic>&#x000a0;=&#x000a0;0.31), or gender (<italic>P</italic>&#x000a0;=&#x000a0;0.72). Breeds represented were mixed-breed (<italic>n</italic>&#x000a0;=&#x000a0;4), French bulldog (<italic>n</italic>&#x000a0;=&#x000a0;4), golden retriever (<italic>n</italic>&#x000a0;=&#x000a0;4), Labrador retriever (<italic>n</italic>&#x000a0;=&#x000a0;3), border collie (<italic>n</italic>&#x000a0;=&#x000a0;2) and 1 each of boxer, cocker spaniel, flat coated retriever, fox terrier, German shepherd, great Dane, Jack Russel terrier, Keeshond, Malinois, mudi, Saint Bernard, Tervuren, and white Swiss shepherd. Of the 30 dogs, 24 underwent magnet resonance imaging and 1 dog underwent computed tomography. Underlying diseases were intracranial neoplasia (<italic>n</italic>&#x000a0;=&#x000a0;8, mannitol group; <italic>n</italic>&#x000a0;=&#x000a0;8, HTS group), intoxication (<italic>n</italic>&#x000a0;=&#x000a0;3, mannitol group; <italic>n</italic>&#x000a0;=&#x000a0;1, HTS group), head trauma (<italic>n</italic>&#x000a0;=&#x000a0;2, mannitol group; <italic>n</italic>&#x000a0;=&#x000a0;1, HTS group), meningoencephalitis (<italic>n</italic>&#x000a0;=&#x000a0;2, mannitol group), hydrocephalus internus (<italic>n</italic>&#x000a0;=&#x000a0;1, HTS group), presumptive hypertensive encephalopathy (<italic>n</italic>&#x000a0;=&#x000a0;1, HTS group), and undetermined in the remaining 3 dogs (HTS group).</p><p>In some samples, the anticipated analyses could not be carried out due to technical constraints (sample clotting or measurement error). In addition, blood samples of 7 dogs at T<sub>60</sub> and a further 3 dogs at T<sub>120</sub> could not be obtained due to euthanasia prior to the measurement time point. The number of samples used for each analysis is presented in Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>. During the two-hour study period, 19 of 30 dogs received intravenous isotonic crystalloid therapy (median, 5&#x000a0;ml/kg; range, 2&#x02013;20&#x000a0;ml/kg).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Osmolarity, hematocrit and platelet counts prior to (T<sub>0</sub>), and at 5 (T<sub>5</sub>), 60 (T<sub>60</sub>) and 120 (T<sub>120</sub>) minutes after administration of mannitol and hypertonic saline (HTS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th rowspan="2">Time point</th><th colspan="4">Osmotherapeutic solution and sample size</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th>Sample size</th><th>Mannitol</th><th>Sample size</th><th>HTS</th></tr></thead><tbody><tr><td rowspan="4">Osmolarity<break/>(RI: 300-310&#x000a0;mOsm/L)</td><td>T<sub>0</sub>
</td><td>15</td><td>312 (308&#x02013;327)</td><td>15</td><td>311 (309&#x02013;320)</td><td>0.89</td></tr><tr><td>T<sub>5</sub>
</td><td>15</td><td>329 (321&#x02013;339)*</td><td>15</td><td>336 (324&#x02013;340)*</td><td>0.96</td></tr><tr><td>T<sub>60</sub>
</td><td>11</td><td>326 (318&#x02013;341)*</td><td>12</td><td>324 (317&#x02013;336)*</td><td>0.62</td></tr><tr><td>T<sub>120</sub>
</td><td>8</td><td>327 (316-334)</td><td>11</td><td>326 (319&#x02013;334)*</td><td>0.59</td></tr><tr><td rowspan="4">Hematocrit<break/>(RI: 0.39-0.57&#x000a0;L/L)</td><td>T<sub>0</sub>
</td><td>15</td><td>0.44 (0.35&#x02013;0.49)</td><td>15</td><td>0.41 (0.37&#x02013;0.49)</td><td>0.97</td></tr><tr><td>T<sub>5</sub>
</td><td>15</td><td>0.37 (0.31&#x02013;0.44)</td><td>15</td><td>0.37 (0.34&#x02013;0.42)</td><td>0.68</td></tr><tr><td>T<sub>60</sub>
</td><td>11</td><td>0.37 (0.35&#x02013;0.41)</td><td>12</td><td>0.38 (0.37&#x02013;0.42)</td><td>0.42</td></tr><tr><td>T<sub>120</sub>
</td><td>8</td><td>0.42 (0.35&#x02013;0.44)</td><td>11</td><td>0.40 (0.36&#x02013;0.42)</td><td>0.70</td></tr><tr><td rowspan="4">Platelet count<break/>(RI: 150-400&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>/L)</td><td>T<sub>0</sub>
</td><td>15</td><td>221 (167&#x02013;375)</td><td>15</td><td>237 (173&#x02013;312)</td><td>0.91</td></tr><tr><td>T<sub>5</sub>
</td><td>15</td><td>202 (157&#x02013;314)</td><td>15</td><td>202 (179&#x02013;287)</td><td>0.82</td></tr><tr><td>T<sub>60</sub>
</td><td>11</td><td>207 (169&#x02013;344)</td><td>12</td><td>177 (134&#x02013;284)</td><td>0.56</td></tr><tr><td>T<sub>120</sub>
</td><td>8</td><td>214 (188&#x02013;393)</td><td>11</td><td>205 (141&#x02013;269)</td><td>0.31</td></tr></tbody></table><table-wrap-foot><p>Values are shown as median (interquartile range), <italic>RI</italic> reference intervals; * values differing significantly from T<sub>0</sub> (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05)</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Rotational thromboelastometry and platelet function analysis closure time prior to (T<sub>0</sub>), and at 5 (T<sub>5</sub>), 60 (T<sub>60</sub>) and 120 (T<sub>120</sub>) minutes after administration of mannitol and hypertonic saline (HTS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th rowspan="2">Time point</th><th colspan="4">Osmotherapeutic solution and sample size</th></tr><tr><th>Mannitol</th><th>Sample size</th><th>HTS</th><th>Sample size</th></tr></thead><tbody><tr><td rowspan="4">Ct<sub>PFA</sub>
<break/>(RI: 42-90s)</td><td>T<sub>0</sub>
</td><td>76 (72-86)</td><td>15</td><td>90 (75-102)</td><td>13</td></tr><tr><td>T<sub>5</sub>
</td><td>
<bold>96 (79-127)</bold>
</td><td>15</td><td>
<bold>96 (77-138)</bold>
</td><td>13</td></tr><tr><td>T<sub>60</sub>
</td><td>85 (76-96)</td><td>11</td><td>
<bold>98 (70-113)</bold>
</td><td>12</td></tr><tr><td>T<sub>120</sub>
</td><td>79 (75-83)</td><td>8</td><td>78 (71-118)</td><td>11</td></tr><tr><td rowspan="4">EXTEM<sup>&#x000ae;</sup> CT<break/>(RI: 20-85&#x000a0;s)</td><td>T<sub>0</sub>
</td><td>42 (37-50)</td><td>15</td><td>42 (35-54)</td><td>15</td></tr><tr><td>T<sub>5</sub>
</td><td>41 (32-45)</td><td>15</td><td>38 (35-50)</td><td>15</td></tr><tr><td>T<sub>60</sub>
</td><td>38 (36-49)</td><td>11</td><td>40 (34-45)</td><td>12</td></tr><tr><td>T<sub>120</sub>
</td><td>43 (29-46)</td><td>9</td><td>41 (36-49)</td><td>11</td></tr><tr><td rowspan="4">EXTEM<sup>&#x000ae;</sup> CFT<break/>(RI: 55-374&#x000a0;s)</td><td>T<sub>0</sub>
</td><td>84 (59-129)</td><td>14</td><td>93 (86-111)</td><td>15</td></tr><tr><td>T<sub>5</sub>
</td><td>114 (74-145)</td><td>14</td><td>115 (102-124)</td><td>14</td></tr><tr><td>T<sub>60</sub>
</td><td>97 (68-105)</td><td>10</td><td>115 (99-190)</td><td>12</td></tr><tr><td>T<sub>120</sub>
</td><td>98 (77-125)</td><td>8</td><td>108 (93-147)</td><td>11</td></tr><tr><td rowspan="4">EXTEM<sup>&#x000ae;</sup> A10<break/>(RI: 17-69&#x000a0;mm)</td><td>T<sub>0</sub>
</td><td>58 (46-62)</td><td>15</td><td>54 (49-61)</td><td>15</td></tr><tr><td>T<sub>5</sub>
</td><td>56 (46-58)</td><td>15</td><td>51 (39-61)</td><td>14</td></tr><tr><td>T<sub>60</sub>
</td><td>57 (53-67)</td><td>11</td><td>54 (53-67)</td><td>12</td></tr><tr><td>T<sub>120</sub>
</td><td>60 (52-63)</td><td>9</td><td>55 (44-56)</td><td>11</td></tr><tr><td rowspan="4">EXTEM<sup>&#x000ae;</sup> &#x003b1;-angle<break/>(RI: 57-86&#x000b0;)</td><td>T<sub>0</sub>
</td><td>73 (61-81)</td><td>14</td><td>72 (69-75)</td><td>15</td></tr><tr><td>T<sub>5</sub>
</td><td>76 (65-71)</td><td>14</td><td>67 (64-71)</td><td>14</td></tr><tr><td>T<sub>60</sub>
</td><td>72 (69-79)</td><td>10</td><td>69 (64-77)</td><td>12</td></tr><tr><td>T<sub>120</sub>
</td><td>69 (65-81)</td><td>8</td><td>70 (65-75)</td><td>11</td></tr><tr><td rowspan="4">EXTEM<sup>&#x000ae;</sup> MCF<break/>(RI: 29-75&#x000a0;mm)</td><td>T<sub>0</sub>
</td><td>68 (52-69)</td><td>15</td><td>66 (59-69)</td><td>15</td></tr><tr><td>T<sub>5</sub>
</td><td>65 (51-67)*</td><td>15</td><td>62 (51-67)</td><td>14</td></tr><tr><td>T<sub>60</sub>
</td><td>67 (64-74)</td><td>11</td><td>63 (50-67)</td><td>12</td></tr><tr><td>T<sub>120</sub>
</td><td>68 (61-71)</td><td>9</td><td>63 (58-65)</td><td>11</td></tr><tr><td rowspan="4">FIBTEM<sup>&#x000ae;</sup> CT<break/>(RI: 18-72&#x000a0;s)</td><td>T<sub>0</sub>
</td><td>38 (31-44)</td><td>15</td><td>42 (36-46)</td><td>14</td></tr><tr><td>T<sub>5</sub>
</td><td>36 (32-44)</td><td>15</td><td>33 (32-39)*</td><td>14</td></tr><tr><td>T<sub>60</sub>
</td><td>39 (33-50)</td><td>11</td><td>35 (30-36)*</td><td>11</td></tr><tr><td>T<sub>120</sub>
</td><td>40 (32-44)</td><td>9</td><td>35 (36-42)*</td><td>10</td></tr><tr><td rowspan="4">FIBTEM<sup>&#x000ae;</sup> A10<break/>(RI: 2-17&#x000a0;mm)</td><td>T<sub>0</sub>
</td><td>12 (10-21)</td><td>15</td><td>11 (6-15)</td><td>14</td></tr><tr><td>T<sub>5</sub>
</td><td>11 (10-17)</td><td>15</td><td>10 (7-13)</td><td>14</td></tr><tr><td>T<sub>60</sub>
</td><td>14 (10-21)</td><td>11</td><td>10 (9-15)</td><td>11</td></tr><tr><td>T<sub>120</sub>
</td><td>16 (11-17)</td><td>9</td><td>11 (8-15)</td><td>10</td></tr><tr><td rowspan="4">FIBTEM<sup>&#x000ae;</sup> &#x003b1;-angle<break/>(RI: 61-88&#x000b0;)</td><td>T<sub>0</sub>
</td><td>75 (65-79)</td><td>13</td><td>67 (65-74)</td><td>10</td></tr><tr><td>T<sub>5</sub>
</td><td>75 (67-81)</td><td>11</td><td>72 (70-75)</td><td>10</td></tr><tr><td>T<sub>60</sub>
</td><td>77 (74-79)</td><td>8</td><td>67 (62-76)</td><td>8</td></tr><tr><td>T<sub>120</sub>
</td><td>76 (64-78)</td><td>8</td><td>72 (61-77)</td><td>6</td></tr><tr><td rowspan="4">FIBTEM<sup>&#x000ae;</sup> MCF<break/>(RI: 3-17&#x000a0;mm)</td><td>T<sub>0</sub>
</td><td>14 (9-20)</td><td>15</td><td>12 (7-16)</td><td>14</td></tr><tr><td>T<sub>5</sub>
</td><td>13 (9-19)*</td><td>15</td><td>11 (8-13)</td><td>13</td></tr><tr><td>T<sub>60</sub>
</td><td>14 (9-18)*</td><td>11</td><td>10 (9-15)</td><td>11</td></tr><tr><td>T<sub>120</sub>
</td><td>15 (13-18)</td><td>9</td><td>12 (9-15)</td><td>10</td></tr></tbody></table><table-wrap-foot><p>
<italic>Ct</italic>
<sub><italic>PFA</italic></sub> platelet closure time, <italic>CT</italic> clotting time, <italic>CFT</italic> clot formation time, <italic>A10</italic> clot firmness amplitude 10&#x000a0;min after CT, <italic>MCF</italic> maximal clot firmness; variables are shown as median (interquartile range), <italic>RI</italic> institutional reference intervals; bold font, median value outside of the RI; *, significant different to T<sub>0</sub> (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05)</p></table-wrap-foot></table-wrap>
</p><sec id="Sec9"><title>Osmolarity, hematocrit and platelet counts</title><p>No significant difference was found in osmolarity, hematocrit or platelet counts between dogs that received mannitol and those that received HTS at any time point (Table <xref rid="Tab1" ref-type="table">1</xref>). Within group comparisons revealed a significant increase in osmolarity at T<sub>5</sub>, T<sub>60</sub> and T<sub>120</sub> after HTS and at T<sub>5</sub> and T<sub>60</sub> after mannitol (Table <xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec10"><title>Platelet function analysis</title><p>At T<sub>0</sub>, Ct<sub>PFA</sub> was significantly longer in the HTS group than in the mannitol group (<italic>P</italic>&#x000a0;=&#x000a0;0.03) but median values were within the RI (Table <xref rid="Tab2" ref-type="table">2</xref>). After treatment, median values were increased above the RI at T<sub>5</sub> (both groups) and T<sub>60</sub> (HTS group). However, no significant difference in percentage relative to values at T<sub>0</sub> was found between the groups at T<sub>5</sub>, T<sub>60</sub>, or T<sub>120</sub> (Table <xref rid="Tab3" ref-type="table">3</xref>) and no difference was found between measurement times within either group (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Rotational thromboelastometry and platelet function analysis closure time (Ct<sub>PFA</sub>) prior to (T<sub>0</sub>), and at 5 (T<sub>5</sub>), 60 (T<sub>60</sub>) and 120 (T<sub>120</sub>) minutes after administration of mannitol and hypertonic saline (HTS) shown as the percentage of values relative to T<sub>0</sub>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="2">Osmotherapeutic solution</th><th/></tr><tr><th>Variable</th><th>Time point</th><th>Mannitol (% from baseline)</th><th>HTS (% from baseline)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td rowspan="3">Ct<sub>PFA</sub>
</td><td>T<sub>5</sub>
</td><td>130 (103-171)</td><td>116 (89-151)</td><td>0.31</td></tr><tr><td>T<sub>60</sub>
</td><td>109 (95-126)</td><td>112 (89-149)</td><td>1.00</td></tr><tr><td>T<sub>120</sub>
</td><td>100 (93-109)</td><td>91 (87-107)</td><td>0.32</td></tr><tr><td rowspan="3">EXTEM<sup>&#x000ae;</sup> CT</td><td>T<sub>5</sub>
</td><td>92 (51-113)</td><td>91 (60-239)</td><td>0.35</td></tr><tr><td>T<sub>60</sub>
</td><td>107 (70-128)</td><td>95 (60-1299</td><td>0.21</td></tr><tr><td>T<sub>120</sub>
</td><td>113 (40-159)</td><td>98 (48-143)</td><td>0.65</td></tr><tr><td rowspan="3">EXTEM<sup>&#x000ae;</sup> CFT</td><td>T<sub>5</sub>
</td><td>115 (73-246)</td><td>118 (84-216)</td><td>0.98</td></tr><tr><td>T<sub>60</sub>
</td><td>111 (62-194)</td><td>113 (83-359)</td><td>0.97</td></tr><tr><td>T<sub>120</sub>
</td><td>115 (80-182)</td><td>109 (70-162)</td><td>0.62</td></tr><tr><td rowspan="3">EXTEM<sup>&#x000ae;</sup> A10</td><td>T<sub>5</sub>
</td><td>97 (61-122)</td><td>98 (16-112)</td><td>0.44</td></tr><tr><td>T<sub>60</sub>
</td><td>103 (86-2014)</td><td>102 (88-260)</td><td>0.68</td></tr><tr><td>T<sub>120</sub>
</td><td>97 (92-127)</td><td>100 (84-215)</td><td>0.37</td></tr><tr><td rowspan="3">EXTEM<sup>&#x000ae;</sup> &#x003b1;-angle</td><td>T<sub>5</sub>
</td><td>98 (65-273)</td><td>96 (20-104)</td><td>0.48</td></tr><tr><td>T<sub>60</sub>
</td><td>99 (71-119)</td><td>98 (71-109)</td><td>0.97</td></tr><tr><td>T<sub>120</sub>
</td><td>100 (71-113)</td><td>100 (93-111)</td><td>0.87</td></tr><tr><td rowspan="3">EXTEM<sup>&#x000ae;</sup> MCF</td><td>T<sub>5</sub>
</td><td>97 (70-300)</td><td>97 (28-104)</td><td>0.86</td></tr><tr><td>T<sub>60</sub>
</td><td>100 (91-469)</td><td>98 (46-106)</td><td>0.12</td></tr><tr><td>T<sub>120</sub>
</td><td>101 (90-446)</td><td>97 (89-111)</td><td>0.22</td></tr><tr><td rowspan="3">FIBTEM<sup>&#x000ae;</sup> CT</td><td>T<sub>5</sub>
</td><td>100 (70-138)</td><td>86 (56-108)</td><td>
<bold>0.01</bold>
</td></tr><tr><td>T<sub>60</sub>
</td><td>111 (72-163)</td><td>81 (55-110)</td><td>
<bold>0.01</bold>
</td></tr><tr><td>T<sub>120</sub>
</td><td>94 (75-142)</td><td>85 (25-126)</td><td>0.11</td></tr><tr><td rowspan="3">FIBTEM<sup>&#x000ae;</sup> A10</td><td>T<sub>5</sub>
</td><td>85 (62-167)</td><td>103 (15-167)</td><td>0.05</td></tr><tr><td>T<sub>60</sub>
</td><td>114 (82-146)</td><td>100 (33-300)</td><td>0.76</td></tr><tr><td>T<sub>120</sub>
</td><td>106 (81-135)</td><td>100 (64-200)</td><td>0.76</td></tr><tr><td rowspan="3">FIBTEM<sup>&#x000ae;</sup> &#x003b1;-angle</td><td>T<sub>5</sub>
</td><td>101 (80-109)</td><td>106 (97-119)</td><td>0.09</td></tr><tr><td>T<sub>60</sub>
</td><td>99 (92-107)</td><td>101 (22 (124)</td><td>0.60</td></tr><tr><td>T<sub>120</sub>
</td><td>100 (93-104)</td><td>96 (83-112)</td><td>0.56</td></tr><tr><td rowspan="3">FIBTEM<sup>&#x000ae;</sup> MCF</td><td>T<sub>5</sub>
</td><td>89 (58-188)</td><td>100 (19-171)</td><td>0.11</td></tr><tr><td>T<sub>60</sub>
</td><td>88 (59-104)</td><td>100 (14-143)</td><td>0.07</td></tr><tr><td>T<sub>120</sub>
</td><td>88 (62-188)</td><td>104 (19-143)</td><td>0.60</td></tr></tbody></table><table-wrap-foot><p>
<italic>Ct</italic>
<sub><italic>PFA</italic></sub> platelet closure time, <italic>CT</italic> clotting time, <italic>CFT</italic> clot formation time, <italic>A10</italic> amplitude after 10&#x000a0;min, <italic>MCF</italic> maximal clot firmness; values shown as median (interquartile range) percentage of measurements relative to T<sub>0; bold font, <italic>P</italic> &#x0003c;0.05</sub>
</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>ROTEM&#x000ae; analysis</title><p>No significant difference was found for any parameter between the groups at T<sub>0</sub> (Table <xref rid="Tab2" ref-type="table">2</xref>) and no significant difference between the groups in percentage relative to T<sub>0</sub> was found for any parameter except for a shortening of FIBTEM&#x000ae; CT at T<sub>5</sub> and T<sub>60</sub> after HTS (Table <xref rid="Tab3" ref-type="table">3</xref>). No significant difference was found between measurement times within either group except for a decrease of EXTEM&#x000ae; MCF at T<sub>5</sub> and FIBTEM&#x000ae; MCF at T<sub>5</sub> and T<sub>60</sub>compared to T<sub>0</sub> in dogs receiving mannitol, and a decrease of FIBTEM&#x000ae; CT at T<sub>5</sub>, T<sub>60</sub>, and T<sub>120</sub> compared to T<sub>0</sub> in dogs receiving HTS (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Median values where within RI at all time points in both groups.</p></sec></sec><sec id="Sec12"><title>Discussion</title><p>The present study evaluated the effects on coagulation of intravenous 20% mannitol and 7.2% HTS in a cohort of dogs with suspected ICH using ROTEM&#x000ae; and PFA&#x000ae; analyses. Only minimal differences in coagulation parameters were found between dogs treated with mannitol and those receiving HTS at currently recommended doses. Indeed, a significant difference between the groups in percent of values relative to baseline (T<sub>0</sub>) was only found for FIBTEM&#x000ae; CT, which showed a shorter time until clot detection at T<sub>5</sub> and T<sub>60</sub> in dogs receiving HTS. This was mirrored by a shorter FIBTEM&#x000ae; CT at T<sub>5</sub>, T<sub>60</sub>, and T<sub>120</sub> compared to T<sub>0</sub> in the HTS group. Furthermore, a short-lived decrease in EXTEM&#x000ae; and FIBTEM&#x000ae; MCF was observed after mannitol. However, median ROTEM&#x000ae; values remained within institutional RIs at all time points in both groups. In contrast, PFA&#x000ae; values increased above institutional RIs after mannitol (T<sub>5</sub>) and HTS (T<sub>5</sub> and T<sub>60</sub>), although no significant differences were found between groups or time points. In terms of the importance of the detected changes, alterations in FIBTEM&#x000ae; CT are most likely of no relevance, as in human medicine only the clot firmness variables (A5, A10, etc., and MCF) of the FIBTEM&#x000ae; assay are used (eg., for deciding on the replacement of fibrinogen sources) [<xref ref-type="bibr" rid="CR25">25</xref>]. The very mild changes in MCF and Ct<sub>PFA</sub> may be signs for a mannitol induced, short-lived fibrin polymerization defect (decrease in MCF FIBTEM&#x000ae;) as well as short lived platelet-fibrin interaction defect, such as impairment of GPIIb/IIIa receptor mediated binding (decrease in MCF EXTEM&#x000ae; combined with impaired platelet function) which might become more prominent after higher doses. Furthermore, plasma osmolarity was significantly increased by 15&#x02013;25&#x000a0;mOsm/L for up to 1 h (mannitol group) and up to 2&#x000a0;h (HTS group), respectively, but no difference between the groups was detected.</p><p>Previous in vitro studies in humans and dogs indicate that both mannitol and HTS affect primary and secondary hemostasis in a dose-dependent fashion by delayed clot formation and impairment of fibrin clot firmness [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Indeed, a 1:22 dilution of whole blood with 7.2% HTS (mimicking a dose of 4&#x000a0;ml/kg) significantly affected Ct<sub>PFA</sub> and ROTEM&#x000ae; EXTEM&#x000ae; CFT and MCF in dogs [<xref ref-type="bibr" rid="CR16">16</xref>]. Moreover, 20% mannitol affected Ct<sub>PFA</sub> and ROTEM&#x000ae; EXTEM&#x000ae; variables to a greater extent than equimolar 3% HTS in dilutions mimicking recommended clinical doses [<xref ref-type="bibr" rid="CR17">17</xref>]. However, given the in vitro nature of these studies and absence of the endothelium and compensatory mechanisms, such as buffering, electrolyte homeostasis, and metabolic degradation and excretion of the drug, results may not reflect in vivo conditions [<xref ref-type="bibr" rid="CR26">26</xref>]. Moreover, in vitro dilution of blood may result in a more significant dilution of coagulation factors than the corresponding in vivo dose, impacting the kinetics of clot formation. Finally, effects of transendothelial fluid shifts, which are a crucial effect of osmotherapy, are essentially eliminated by in vitro studies.</p><p>The findings of the present study only partially confirm recent in vitro findings [<xref ref-type="bibr" rid="CR17">17</xref>]. The less pronounced effect of mannitol in the present study may to some extent be due to disparate osmolarities of the HTS solutions evaluated (3% HTS in the previous in vitro study compared to 7.2% in the present study). Indeed, hyperosmotic stress may result in impaired enzymatic function in the clotting cascade, slower clot formation and a weaker clot [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In the present study no significant difference in plasma osmolarity was found between the two groups despite the higher osmolarity and more rapid administration of HTS. Likewise, no significant difference in plasma osmolarity was found between 7.2% NaCl/HES 200/0.5 and 15% mannitol in a previous study in 40 adult neurosurgical patients [<xref ref-type="bibr" rid="CR27">27</xref>]. This may, in part, explain the lack of difference in ROTEM&#x000ae; and PFA&#x000ae; parameters between the two osmotherapeutic groups. However, the extent to which the changes observed in ROTEM&#x000ae; and PFA&#x000ae; parameters were due to increased osmolarity, increased sodium load, or to additional hemostatic disturbances from each hyperosmolar molecule itself remains unclear. Lastly, the volume administered in the present study was lower than dilutions used in some previous in vitro studies, which may have masked potential coagulation impairing effects at higher doses.</p><p>Similar to the current findings, in two recent studies in people undergoing elective craniotomy or suffering from traumatic brain injury, respectively, no difference in standard coagulation tests and ROTEM&#x000ae; analysis was found between patients administered 20% mannitol and those receiving 3% HTS [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p>To the authors&#x02019; knowledge, the present study is the first investigation evaluating platelet function with PFA&#x000ae; after intravenous administration of mannitol or HTS in dogs. Despite the 30% increase in Ct<sub>PFA</sub> after mannitol at T<sub>5</sub> and some PFA values above the RI in both groups, the changes did not reach statistical significance and returned to normal within the two-hour study period. A clear advantage of one of the osmotherapeutics to avert platelet dysfunction was therefore not evident, although mannitol may have more pronounced but shorter lived effects compared to HTS.</p><p>In contrast to the aforementioned in vitro studies [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], dogs in the present study were not healthy as they all were affected by conditions causing suspected ICH. Of the included dogs, 53% had intracranial neoplasia, albeit equally distributed between both treatment groups. Furthermore, 5 dogs (<italic>n</italic>&#x000a0;=&#x000a0;3, HTS group; <italic>n</italic>&#x000a0;=&#x000a0;2, mannitol group) included in the study had received one dose of glucocorticoids (&#x02264;1&#x000a0;mg/kg) within 7&#x000a0;days prior to the study, which may be expected to increase clot strength and decrease clot lysis in thromboelastography [<xref ref-type="bibr" rid="CR29">29</xref>]. However, effects on thromboelastographic amplitude and clot lysis in the respective study were found after two 2 and 4&#x000a0;days of treatment, respectively, with an immunosuppressive dose of prednisone (median dose 2.07&#x000a0;mg/kg per 24&#x000a0;h). In contrast, the dogs in the present study received prednisolone in a lower dose and only once. Nevertheless, given heterogeneous diseases and previous treatments, some dogs included in this study were expected to have some abnormal initial PFA&#x000ae; or ROTEM&#x000ae; measurements. Indeed, MCF values were above the RI in EXTEM&#x000ae; (<italic>n</italic>&#x000a0;=&#x000a0;1) and FIBTEM&#x000ae; (<italic>n</italic>&#x000a0;=&#x000a0;5). This confounder was cancelled out in the evaluation of differences between time points by using the percentage of parameters relative to those measured at T<sub>0</sub> instead of absolute values, allowing evaluation of a cohort that truly represents the target population of dogs receiving osmotherapy. Given the small numbers of dogs affected by different diseases, no analyses of associations between disease and coagulation parameters was performed and further studies are needed to establish whether certain conditions leading the ICH are associated with coagulation abnormalities in dogs.</p><p>The current guidelines for viscoelastic coagulation testing recommend blood sampling for ROTEM&#x000ae; by atraumatic puncture of the jugular vein [<xref ref-type="bibr" rid="CR30">30</xref>]. However, as compression of the jugular vein is not recommended in dogs with ICH, samples were taken from the lateral saphenous veins in the present study [<xref ref-type="bibr" rid="CR18">18</xref>]. The extent to which this may have affected results is not clear.</p><p>Artefactual hypercoagulability using ROTEM&#x000ae; analysis has been shown to occur due to low red blood cell mass [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Likewise, low hematocrits and low platelet count was found to prolong PFA&#x000ae; results [<xref ref-type="bibr" rid="CR23">23</xref>]. In the present study, some dogs were slightly anemic following administration of osmotherapeutics but hematocrits did not fall below 0.30&#x000a0;L/L and platelet counts not fall below 100&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>/L in any dog at any time point, which is within the current recommendations for accurate PFA&#x000ae; testing [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>The current study has potential limitations. Firstly, simultaneous standard coagulation testing (prothrombin time (PT), partial thromboplastin time (aPTT), and fibrinogen concentration) was not assessed. Although ROTEM&#x000ae; analysis enables dynamic assessment of whole blood coagulation and platelet function, standard coagulation testing may have helped in the interpretation of the clinical relevance of findings. However, both PT and aPTT are essentially limited to answering the question whether any intervention exerts effects on thrombin generation, depending on the coagulation factors reflected in the respective assay. As we were not expecting the interventions in our study to exert impacts on thrombin generation, the information obtainable by additional PT and aPTT assays would be limited to detect potential effects induced by dilution. Furthermore, both poor and good associations between standard coagulation tests and ROTEM&#x000ae; analyses have been reported [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], and information about platelet function, fibrin polymerization, and platelet interaction with fibrin is not provided by plasmatic coagulation tests. Further, although there are no results of any conventional fibrinogen assay available, variables of clot firmness (MCF and A10) of ROTEM&#x000ae; FIBTEM&#x000ae; assays are highly correlated with the fibrinogen concentration [<xref ref-type="bibr" rid="CR31">31</xref>] and adequately provide information about potential fibrin-polymerization defects that are not detectable using standard lab tests. Even if potentially elevated fibrinogen concentrations in some of the dogs might have alleviated coagulation impairment, importantly no relevant alteration of fibrin polymerization was found after osmotherapy in the present study.</p><p>Another limitation was that some dogs received additional crystalloid fluid therapy during the study period as treatment was largely at the discretion of the clinicians. Previous in vitro studies in dogs demonstrated a dilutional coagulopathy caused by 0.9% saline on viscoelastic coagulation and PFA&#x000ae; testing [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Contrariwise, a recent in vivo study in healthy anesthetized dogs administered with a 15&#x000a0;ml/kg-bolus of isotonic buffered crystalloids did not led to relevant ROTEM&#x000ae; and PFA&#x000ae; abnormalities [<xref ref-type="bibr" rid="CR36">36</xref>]. Nevertheless, simultaneous crystalloid fluid therapy might have impacted results in individual dogs in the present study. Lastly, although the previous in vitro study evaluated a 3% HTS solution, dogs in the present study were given a 7.2% HTS solution as this was the established institutional treatment protocol for dogs with ICH. It is likely that more significant differences between groups would have been found had mannitol been compared with 3% HTS instead of 7.2% HTS.</p></sec><sec id="Sec13"><title>Conclusion</title><p>In conclusion, results of this pilot study suggest that mannitol and HTS do not differ in their effects on coagulation when administered in the currently recommended doses in dogs with suspected ICH. Moreover, no clinically relevant impairment of whole blood coagulation was found following treatment with either solution, whereas a short-lived impairment of platelet function was found after both solutions. Further studies are warranted before recommendations can be made with regards to treatment of individual animals.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>A10</term><def><p>Amplitude after 10&#x000a0;min</p></def></def-item><def-item><term>CFT</term><def><p>Clot formation time</p></def></def-item><def-item><term>CT</term><def><p>Clotting time</p></def></def-item><def-item><term>Ct<sub>PFA</sub></term><def><p>Platelet function analysis closure time</p></def></def-item><def-item><term>HTS</term><def><p>Hypertonic saline</p></def></def-item><def-item><term>ICH</term><def><p>Intracranial hypertension</p></def></def-item><def-item><term>MCF</term><def><p>Maximum clot firmness</p></def></def-item><def-item><term>PFA&#x000ae;</term><def><p>Platelet function analyzer</p></def></def-item><def-item><term>RI</term><def><p>Reference intervals</p></def></def-item><def-item><term>ROTEM&#x000ae;</term><def><p>Rotational thromboelastometry</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The authors would like to thank Axon Lab AG, T&#x000e4;fernstrasse 15, 5405 Baden, Switzerland for provision and service of the ROTEM&#x000ae;. The authors would like to thank the Specialization Commission (SPEZKO) of the Vetsuisse Faculty of Bern, Switzerland for partial funding of the study.</p><sec id="FPar1"><title>Funding</title><p>Supported in part by the Specialization Commission (SPEZKO) of the Vetsuisse Faculty of Bern, Switzerland.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets supporting the conclusions of this article are included within the article. The raw data are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>IDY participated in the design of the study, performed blood samplings, ROTEM and PFA analyses, and wrote the manuscript; DH assisted with acquisition of patients and revised the manuscript; JH performed the statistical analyses and substantially assisted in writing the manuscript; DD helped with data interpretation and assisted with writing the manuscript; KNA conceived and designed the study, interpreted the data, and wrote the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>DD has received honoraria for scientific lectures and traveling support from CSL Behring GmbH, Marburg Germany; TEM international GmbH, Munich, Germany; Abbot Point-of-Care, Princeton, NJ, USA. DD serves as an advisory board member for Werfen GmbH, Kirchheim bei M&#x000fc;nchen, Germany.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Consent from the owners was obtained.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The study protocol was approved by University of Bern and the Animal Experiment Committee of the Swiss Federal Veterinary Office (No. BE 90/13). Informed owner consent was obtained before study enrollment.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grape</surname><given-names>S</given-names></name><name><surname>Ravussin</surname><given-names>P</given-names></name></person-group><article-title>PRO: osmotherapy for the treatment of acute intracranial hypertension</article-title><source>J Neurosurg Anest</source><year>2012</year><volume>24</volume><issue>4</issue><fpage>402</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1097/01.ana.0000419729.52363.64</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>ME</given-names></name></person-group><article-title>Osmotherapy for intracranial hypertension: mannitol versus hypertonic saline</article-title><source>Continuum</source><year>2012</year><volume>18</volume><issue>3</issue><fpage>640</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">22810253</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurg. 2017;80(1):1&#x02013;15.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickard</surname><given-names>AC</given-names></name><name><surname>Smith</surname><given-names>JE</given-names></name><name><surname>Newell</surname><given-names>P</given-names></name><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Kehoe</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>C</given-names></name></person-group><article-title>Salt or sugar for your injured brain? A meta-analysis of randomised controlled trials of mannitol versus hypertonic sodium solutions to manage raised intracranial pressure in traumatic brain injury</article-title><source>Emerg Med J</source><year>2014</year><volume>31</volume><issue>8</issue><fpage>679</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1136/emermed-2013-202679</pub-id><pub-id pub-id-type="pmid">23811861</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broderick</surname><given-names>J</given-names></name><name><surname>Connolly</surname><given-names>S</given-names></name><name><surname>Feldmann</surname><given-names>E</given-names></name><name><surname>Hanley</surname><given-names>D</given-names></name><name><surname>Kase</surname><given-names>C</given-names></name><name><surname>Krieger</surname><given-names>D</given-names></name><etal/></person-group><article-title>Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association stroke council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group</article-title><source>Circulation</source><year>2007</year><volume>116</volume><issue>16</issue><fpage>e391</fpage><lpage>e413</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.183689</pub-id><pub-id pub-id-type="pmid">17938297</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>M</given-names></name><name><surname>McCurdy</surname><given-names>DK</given-names></name><name><surname>Ramirez</surname><given-names>MA</given-names></name></person-group><article-title>Differences between saline and Mannitol Diuresis in Hydropenic man</article-title><source>J Clin Invest</source><year>1965</year><volume>44</volume><fpage>182</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1172/JCI105133</pub-id><pub-id pub-id-type="pmid">14260160</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prough</surname><given-names>DS</given-names></name><name><surname>Whitley</surname><given-names>JM</given-names></name><name><surname>Taylor</surname><given-names>CL</given-names></name><name><surname>Deal</surname><given-names>DD</given-names></name><name><surname>DeWitt</surname><given-names>DS</given-names></name></person-group><article-title>Regional cerebral blood flow following resuscitation from hemorrhagic shock with hypertonic saline. Influence of a subdural mass</article-title><source>Anesthesiology</source><year>1991</year><volume>75</volume><issue>2</issue><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1097/00000542-199108000-00021</pub-id><pub-id pub-id-type="pmid">1677548</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>L</given-names></name></person-group><article-title>Fluid Management in Patients with trauma: restrictive versus liberal approach</article-title><source>Vet Clin North Am Small Anim Pract</source><year>2017</year><volume>47</volume><issue>2</issue><fpage>397</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2016.10.014</pub-id><pub-id pub-id-type="pmid">27914759</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilder</surname><given-names>DM</given-names></name><name><surname>Reid</surname><given-names>TJ</given-names></name><name><surname>Bakaltcheva</surname><given-names>IB</given-names></name></person-group><article-title>Hypertonic resuscitation and blood coagulation: in vitro comparison of several hypertonic solutions for their action on platelets and plasma coagulation</article-title><source>Thromb Res</source><year>2002</year><volume>107</volume><issue>5</issue><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/S0049-3848(02)00335-3</pub-id><pub-id pub-id-type="pmid">12479887</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>TS</given-names></name><name><surname>Tan</surname><given-names>KH</given-names></name><name><surname>Ng</surname><given-names>HP</given-names></name><name><surname>Loh</surname><given-names>MW</given-names></name></person-group><article-title>The effects of hypertonic saline solution (7.5%) on coagulation and fibrinolysis: an in vitro assessment using thromboelastography</article-title><source>Anaesthesia</source><year>2002</year><volume>57</volume><issue>7</issue><fpage>644</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2044.2002.02603.x</pub-id><pub-id pub-id-type="pmid">12059821</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marko</surname><given-names>NF</given-names></name></person-group><article-title>Hypertonic saline, not mannitol, should be considered gold-standard medical therapy for intracranial hypertension</article-title><source>Crit Care</source><year>2012</year><volume>16</volume><issue>1</issue><fpage>113</fpage><pub-id pub-id-type="pmid">22353146</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanke</surname><given-names>AA</given-names></name><name><surname>Maschler</surname><given-names>S</given-names></name><name><surname>Schochl</surname><given-names>H</given-names></name><name><surname>Floricke</surname><given-names>F</given-names></name><name><surname>Gorlinger</surname><given-names>K</given-names></name><name><surname>Zanger</surname><given-names>K</given-names></name><etal/></person-group><article-title>In vitro impairment of whole blood coagulation and platelet function by hypertonic saline hydroxyethyl starch</article-title><source>Scand J Trauma Resusc Emerg Med</source><year>2011</year><volume>19</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/1757-7241-19-12</pub-id><pub-id pub-id-type="pmid">21310047</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thongrong</surname><given-names>C</given-names></name><name><surname>Kong</surname><given-names>N</given-names></name><name><surname>Govindarajan</surname><given-names>B</given-names></name><name><surname>Allen</surname><given-names>D</given-names></name><name><surname>Mendel</surname><given-names>E</given-names></name><name><surname>Bergese</surname><given-names>SD</given-names></name></person-group><article-title>Current purpose and practice of hypertonic saline in neurosurgery: a review of the literature</article-title><source>World Neurosurg</source><year>2014</year><volume>82</volume><issue>6</issue><fpage>1307</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2013.02.027</pub-id><pub-id pub-id-type="pmid">23402866</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luostarinen</surname><given-names>T</given-names></name><name><surname>Niiya</surname><given-names>T</given-names></name><name><surname>Schramko</surname><given-names>A</given-names></name><name><surname>Rosenberg</surname><given-names>P</given-names></name><name><surname>Niemi</surname><given-names>T</given-names></name></person-group><article-title>Comparison of hypertonic saline and mannitol on whole blood coagulation in vitro assessed by thromboelastometry</article-title><source>Neurocrit Care</source><year>2011</year><volume>14</volume><issue>2</issue><fpage>238</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1007/s12028-010-9475-6</pub-id><pub-id pub-id-type="pmid">21369792</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Palazon</surname><given-names>J</given-names></name><name><surname>Fuentes-Garcia</surname><given-names>D</given-names></name><name><surname>Domenech-Asensi</surname><given-names>P</given-names></name><name><surname>Piqueras-Perez</surname><given-names>C</given-names></name><name><surname>Falcon-Arana</surname><given-names>L</given-names></name><name><surname>Burguillos-Lopez</surname><given-names>S</given-names></name></person-group><article-title>Equiosmolar solutions of hypertonic saline and Mannitol do not impair blood coagulation during elective intracranial surgery</article-title><source>J Neurosurg Anesthes</source><year>2015</year><volume>29</volume><issue>1</issue><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/ANA.0000000000000255</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurlod</surname><given-names>VA</given-names></name><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Francey</surname><given-names>T</given-names></name><name><surname>Schweighauser</surname><given-names>A</given-names></name><name><surname>Adamik</surname><given-names>KN</given-names></name></person-group><article-title>Comparison of the in vitro effects of saline, hypertonic hydroxyethyl starch, hypertonic saline, and two forms of hydroxyethyl starch on whole blood coagulation and platelet function in dogs</article-title><source>J Vet Emerg Crit Care</source><year>2015</year><volume>25</volume><issue>4</issue><fpage>474</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1111/vec.12320</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamik</surname><given-names>KN</given-names></name><name><surname>Butty</surname><given-names>E</given-names></name><name><surname>Howard</surname><given-names>J</given-names></name></person-group><article-title>In vitro effects of 3% hypertonic saline and 20% mannitol on canine whole blood coagulation and platelet function</article-title><source>BMC Vet Res</source><year>2015</year><volume>11</volume><fpage>242</fpage><pub-id pub-id-type="doi">10.1186/s12917-015-0555-x</pub-id><pub-id pub-id-type="pmid">26403081</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sande</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>C</given-names></name></person-group><article-title>Traumatic brain injury: a review of pathophysiology and management</article-title><source>J Vet Emerg Crit Care</source><year>2010</year><volume>20</volume><issue>2</issue><fpage>177</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1111/j.1476-4431.2010.00527.x</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driessen</surname><given-names>B</given-names></name><name><surname>Brainard</surname><given-names>B</given-names></name></person-group><article-title>Fluid therapy for the traumatized patient</article-title><source>J Vet Emerg Crit Care</source><year>2006</year><volume>16</volume><issue>4</issue><fpage>276</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1111/j.1476-4431.2006.00184.x</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bittermann</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name><name><surname>Henke</surname><given-names>D</given-names></name><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Gorgas</surname><given-names>D</given-names></name></person-group><article-title>Magnetic resonance imaging signs of presumed elevated intracranial pressure in dogs</article-title><source>Vet J</source><year>2014</year><volume>201</volume><issue>1</issue><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2014.04.020</pub-id><pub-id pub-id-type="pmid">24888678</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukushima</surname><given-names>U</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Okano</surname><given-names>S</given-names></name><name><surname>Oyamada</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Hagio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Non-invasive diagnosis of ischemic brain damage after cardiopulmonary resuscitation in dogs by using transcranial Doppler ultrasonography</article-title><source>Vet Radiol Ultrasound</source><year>2000</year><volume>41</volume><issue>2</issue><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/j.1740-8261.2000.tb01473.x</pub-id><pub-id pub-id-type="pmid">10779079</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>SR</given-names></name><name><surname>Radaelli</surname><given-names>ST</given-names></name><name><surname>McDonnell</surname><given-names>JJ</given-names></name></person-group><article-title>The prognostic value of the modified Glasgow coma scale in head trauma in dogs</article-title><source>J Vet Intern Med</source><year>2001</year><volume>15</volume><issue>6</issue><fpage>581</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1111/j.1939-1676.2001.tb01594.x</pub-id><pub-id pub-id-type="pmid">11817064</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callan</surname><given-names>MB</given-names></name><name><surname>Giger</surname><given-names>U</given-names></name></person-group><article-title>Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs</article-title><source>Am J Vet Res</source><year>2001</year><volume>62</volume><issue>5</issue><fpage>652</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.2460/ajvr.2001.62.652</pub-id><pub-id pub-id-type="pmid">11341380</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>McMichael</surname><given-names>M</given-names></name><name><surname>Galligan</surname><given-names>A</given-names></name><name><surname>Gilor</surname><given-names>S</given-names></name><name><surname>Hoh</surname><given-names>CM</given-names></name></person-group><article-title>Clot formation in canine whole blood as measured by rotational thromboelastometry is influenced by sample handling and coagulation activator</article-title><source>Blood Coagul Fibrinolysis</source><year>2010</year><volume>21</volume><issue>7</issue><fpage>692</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">20739876</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorlinger</surname><given-names>K</given-names></name><name><surname>Dirkmann</surname><given-names>D</given-names></name><name><surname>Hanke</surname><given-names>AA</given-names></name><name><surname>Kamler</surname><given-names>M</given-names></name><name><surname>Kottenberg</surname><given-names>E</given-names></name><name><surname>Thielmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study</article-title><source>Anesthesiology</source><year>2011</year><volume>115</volume><issue>6</issue><fpage>1179</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">21970887</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scharbert</surname><given-names>G</given-names></name><name><surname>Kozek-Langenecker</surname><given-names>S</given-names></name></person-group><article-title>Limitations of in vitro experiments on hydroxyethyl starch solutions</article-title><source>Anesth Analg</source><year>2007</year><volume>105</volume><issue>3</issue><fpage>885</fpage><pub-id pub-id-type="doi">10.1213/01.ane.0000270265.36079.2e</pub-id><pub-id pub-id-type="pmid">17717268</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harutjunyan</surname><given-names>L</given-names></name><name><surname>Holz</surname><given-names>C</given-names></name><name><surname>Rieger</surname><given-names>A</given-names></name><name><surname>Menzel</surname><given-names>M</given-names></name><name><surname>Grond</surname><given-names>S</given-names></name><name><surname>Soukup</surname><given-names>J</given-names></name></person-group><article-title>Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients - a randomized clinical trial</article-title><source>Crit Care</source><year>2005</year><volume>9</volume><issue>5</issue><fpage>R530</fpage><lpage>R540</lpage><pub-id pub-id-type="doi">10.1186/cc3767</pub-id><pub-id pub-id-type="pmid">16277715</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Wang H, Cao H, Zhang X, Ge L, Bie L. The effect of hypertonic saline and mannitol on coagulation in moderate traumatic brain injury patients. Am J Emerg Med. 2017; (Epub ahead of print)</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flint</surname><given-names>SK</given-names></name><name><surname>Abrams-Ogg</surname><given-names>AC</given-names></name><name><surname>Kruth</surname><given-names>SA</given-names></name><name><surname>Bersenas</surname><given-names>AM</given-names></name><name><surname>Wood</surname><given-names>RD</given-names></name></person-group><article-title>Independent and combined effects of prednisone and acetylsalicylic acid on thromboelastography variables in healthy dogs</article-title><source>Am J Vet Res</source><year>2011</year><volume>72</volume><issue>10</issue><fpage>1325</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.2460/ajvr.72.10.1325</pub-id><pub-id pub-id-type="pmid">21962274</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flatland</surname><given-names>B</given-names></name><name><surname>Koenigshof</surname><given-names>AM</given-names></name><name><surname>Rozanski</surname><given-names>EA</given-names></name><name><surname>Goggs</surname><given-names>R</given-names></name><name><surname>Wiinberg</surname><given-names>B</given-names></name></person-group><article-title>Systematic evaluation of evidence on veterinary viscoelastic testing part 2: sample acquisition and handling</article-title><source>J Vet Emerg Crit Care</source><year>2014</year><volume>24</volume><issue>1</issue><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/vec.12142</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Galligan</surname><given-names>A</given-names></name><name><surname>Swanson</surname><given-names>KS</given-names></name></person-group><article-title>In vitro hypercoagulability on whole blood thromboelastometry associated with in vivo reduction of circulating red cell mass in dogs</article-title><source>Vet Clin Path</source><year>2014</year><volume>43</volume><issue>2</issue><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1111/vcp.12127</pub-id><pub-id pub-id-type="pmid">24588681</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>McMichael</surname><given-names>MA</given-names></name><name><surname>Gilor</surname><given-names>S</given-names></name><name><surname>Galligan</surname><given-names>AJ</given-names></name><name><surname>Hoh</surname><given-names>CM</given-names></name></person-group><article-title>Correlation of hematocrit, platelet concentration, and plasma coagulation factors with results of thromboelastometry in canine whole blood samples</article-title><source>Am J Vet Res</source><year>2012</year><volume>73</volume><issue>6</issue><fpage>789</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.2460/ajvr.73.6.789</pub-id><pub-id pub-id-type="pmid">22620692</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>T</given-names></name><name><surname>Spielmann</surname><given-names>N</given-names></name><name><surname>Mauch</surname><given-names>J</given-names></name><name><surname>Madjdpour</surname><given-names>C</given-names></name><name><surname>Speer</surname><given-names>O</given-names></name><name><surname>Schmugge</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of thromboelastometry (ROTEM(R)) with standard plasmatic coagulation testing in paediatric surgery</article-title><source>Br J Anaesth</source><year>2012</year><volume>108</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1093/bja/aer342</pub-id><pub-id pub-id-type="pmid">22086509</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagemo</surname><given-names>JS</given-names></name><name><surname>Christiaans</surname><given-names>SC</given-names></name><name><surname>Stanworth</surname><given-names>SJ</given-names></name><name><surname>Brohi</surname><given-names>K</given-names></name><name><surname>Johansson</surname><given-names>PI</given-names></name><name><surname>Goslings</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study</article-title><source>Crit Care</source><year>2015</year><volume>19</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/s13054-015-0823-y</pub-id><pub-id pub-id-type="pmid">25888032</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>BR</given-names></name><name><surname>de Laforcade</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Palmisano</surname><given-names>J</given-names></name><name><surname>Meola</surname><given-names>D</given-names></name><name><surname>Rozanski</surname><given-names>E</given-names></name></person-group><article-title>Effects of in vitro hemodilution with crystalloids, colloids, and plasma on canine whole blood coagulation as determined by kaolin-activated thromboelastography</article-title><source>J Vet Emerg Crit Care</source><year>2016</year><volume>26</volume><issue>1</issue><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/vec.12345</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuteler</surname><given-names>A</given-names></name><name><surname>Axiak-Flammer</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Adamik</surname><given-names>KN</given-names></name></person-group><article-title>Comparison of the effects of a balanced crystalloid-based and a saline-based tetrastarch solution on canine whole blood coagulation and platelet function</article-title><source>J Vet Emerg Crit Care</source><year>2017</year><volume>27</volume><issue>1</issue><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/vec.12556</pub-id></element-citation></ref></ref-list></back></article>